ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

Ratings for AnaptysBio ANAB were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn. Contact: Nick ...

On Thursday, H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock.

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Truist notes that AnaptysBio (ANAB) reported the “much anticipated ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was acquired at an average price of $12.95 ...